Richard I. Steinhart
Known title: DirectorCIK: 0001293789
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Atossa Announces Stapled CVR Plan and Raises Price Target. Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.
Transaction History
| ATNM | ▲ Buy | Grant | 62,800 | $0 | 9/2/2026 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 35 | — | 6/15/2026 | View on chart |
| BTAI | ▼ Sell | Open Market | 6,845 | $7K | 5/20/2026 | View on chart |
| ATOS | ▲ Buy | Grant | 10,000 | $0 | 5/12/2026 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 17,500 | — | 5/4/2026 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 9,000 | — | 5/1/2026 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 35 | — | 3/15/2026 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 33 | — | 3/14/2026 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 35 | — | 12/15/2025 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 33 | — | 12/14/2025 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 35 | — | 9/15/2025 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 33 | — | 9/14/2025 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 625 | — | 7/22/2025 | View on chart |
| BTAI | ▲ Buy | Grant | 4,375 | — | 7/22/2025 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 35 | — | 6/15/2025 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 33 | — | 6/14/2025 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 34 | — | 3/15/2025 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 31 | — | 3/14/2025 | View on chart |
| BTAI | ▼ Sell | Open Market | 372 | $133 | 12/16/2024 | View on chart |
| BTAI | ▼ Sell | Open Market | 205 | $74 | 12/16/2024 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 562 | — | 12/15/2024 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 521 | — | 12/14/2024 | View on chart |
| BTAI | ▼ Sell | Open Market | 7,175 | $4K | 10/3/2024 | View on chart |
| BTAI | ▲ Buy | Grant | 21,250 | — | 9/17/2024 | View on chart |
| BTAI | ▼ Sell | Open Market | 356 | $246 | 9/16/2024 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 563 | — | 9/15/2024 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 521 | — | 9/14/2024 | View on chart |
| BTAI | ▼ Sell | Open Market | 372 | $470 | 6/17/2024 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 562 | — | 6/15/2024 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 521 | — | 6/14/2024 | View on chart |
| BTAI | ▼ Sell | Open Market | 1,069 | $3K | 4/4/2024 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 2,250 | — | 3/15/2024 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 521 | — | 3/14/2024 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 521 | — | 12/14/2023 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 521 | — | 9/14/2023 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 521 | — | 6/14/2023 | View on chart |
| BTAI | ▼ Sell | Open Market | 5,000 | $136K | 5/15/2023 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 5,000 | — | 5/14/2023 | View on chart |
| BTAI | ▼ Sell | Open Market | 2,084 | $41K | 3/15/2023 | View on chart |
| BTAI | ▲ Buy | Option Exercise | 2,084 | — | 3/14/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Actinium Announces ATNM-400 Presentation and CFO Appointment
Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.
Actinium Announces ATNM-400 Presentation and CFO Appointment. Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.